Announcements

Grant awarded to Johns Hopkins University for protocol development

FCF is pleased to announce a new one-year grant award to Mark Yarchoan of Johns Hopkins University in Baltimore, MD to support the development of a protocol for a potential clinical trial. In 2020, the Johns Hopkins team began a phase I clinical trial of an experimental vaccine containing a peptide (small segment of a protein) that corresponds to the junction region between the two parts of FLC’s characteristic chimeric protein. Patients enrolled in that trial also simultaneously received two FDA-approved checkpoint inhibitors – Opdivo (nivolumab) and Yervoy (ipilimumab).

This new effort is focused on designing an appropriate follow-up clinical study as soon as possible, to build on the learnings of the peptide vaccine effort and better understand factors that can limit the immune system’s ability to fight FLC.

JanFebMarAprMayJunJulAugSepOctNovDec